Phase II trial of ToleroMune (Circassia) shows benefits for Cat Allergy two years after treatment

Results of a Phase II clinical study show that a course of just four doses of ToleroMune Cat Allergy therapy (T cell vaccine), from Circassia Ltd, maintained improvements in patients' symptoms two years after the start of treatment. The study originally measured improvements in nasal and ocular allergy symptoms (Total Rhinoconjunctivitis Symptom Score; TRSS) in 202 patients, following treatment with ToleroMune therapy or placebo. Two years later, and having received no further ToleroMune treatment, 50 of the original patients returned to reassess their symptoms while exposed to cat allergens.

The results show that at the end of the challenge, patients who had previously been treated with four doses of ToleroMune therapy over 12 weeks had a significant improvement in symptoms two years later, compared with placebo (p<0.05; 50.0% trss improvement on toleromune treatment vs 14.9% on placebo). these patients also maintained a substantial reduction in symptoms throughout their entire exposure to cat allergens over the challenge (38.3% trss improvement vs 13.4% on placebo). the results were presented at the 2013 annual meeting of the american academy of allergy, asthma and immunology.>